


AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No. PB60266USW	
Applicant(s): Borthwick et al.						
Application No. 10/561,259	Filing Date 4/28/06	Examiner Golam M. Shameem	Customer No. 23347	Group Art Unit 1626	Confirmation No. 2447	
Invention: 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS						
<u>COMMISSIONER FOR PATENTS:</u>						
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	11 -	20 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	2 -	3 =	0	x \$210.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 _____ <i>Signature</i>			Dated: 7/24/2009			
R. Steve Thomas, Reg. No. 52,284 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8406 Facsimile: (919) 483-7988			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ <div style="text-align: center;">(Date)</div> <div style="text-align: center;">_____ Signature of Person Mailing Correspondence</div> <div style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</div>			
CC:						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Borthwick, *et al.*

Confirmation No.: 2447

Serial No.: 10/561,259

Docket No.: PB60266USW

Filed: April 28, 2006

Examiner: Sameem, Golam

For: 2-PYRROLIDONE DERIVATIVES AND USE Art Unit: 1626
THEREOF AS FACTOR XA INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Dear Sir:

This communication is in response to the Office Action mailed on April 22, 2008, setting a three-month period for response that expires on July 22, 2008. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith. If any additional fees for the accompanying response are required, Applicants request that this be considered a Petition therefor and authorize the Commissioner to charge additional fees to Deposit Account No. 07-1392.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 9 of this paper.